Ireland Fears Shortage Of Medicines Co-Labeled With UK Following Brexit
Executive Summary
By encouraging and facilitating the joint labeling of medicines with the UK, Ireland has ensured the availability of the necessary human and veterinary medicines despite its small market size. But Brexit is causing concern that medicines for smaller patient populations may not be commercially viable if they have to be packaged separately for the Irish market.
You may also be interested in...
EU Regulatory Network Reaches ‘Point Of No Return,’ German Official Says Of Brexit
A senior German regulator says that changes the EU medicines regulatory network has been making since the UK announced it was leaving the EU means that nothing will ever be the same again irrespective of whether the UK is allowed to remain in network as part of a Brexit deal.
Change Your RMS In Just Days – And For Free, Ireland’s Brexit Guidance Says
Ireland’s Health Products Regulatory Authority has moved quickly in issuing guidance for drug companies on making Brexit-related changes.
Change And More Change: That’s What Brexit Means For Drug Companies
The EU medicines network has issued a long list of changes that drug companies with activities in the UK will have to make if they are to continue to be located from a regulatory standpoint in the European Economic Area following Brexit. Aspects affected include the location of orphan designation holders, qualified persons for pharmacovigilance, companies’ manufacturing and batch release sites and maintenance of SME status.